# Tisotumab vedotin

Source: https://onco.cc/drugs/tisotumab-vedotin/  
OnCo record `tisotumab-vedotin` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Tisotumab vedotin is an ADC against tissue factor, the first to show a survival benefit in recurrent cervical cancer.

## Summary

Tisotumab vedotin is a fully human anti-tissue-factor IgG1 antibody joined to the microtubule inhibitor MMAE through a cleavable mc-vc-PABC linker; tissue factor is abundant on cervical cancer cells, and the released payload kills the target cell and its neighbours. It is given at 2 mg/kg every 3 weeks for recurrent or metastatic cervical cancer after chemotherapy. Accelerated approval in 2021 followed innovaTV 204, and full approval in 2024 followed innovaTV 301, in which overall survival was 11.5 versus 9.5 months against chemotherapy in second- and third-line disease, the first survival benefit in this setting. Conjunctival disorders affected 37 percent, so eye exams, steroid and vasoconstrictor drops and cold packs during infusion are required; epistaxis (26 percent) and haemorrhage (21 percent) reflect the tissue-factor target.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-04
- Brand: Tivdak
- Modality: ADC
- Mechanism: Human anti-tissue-factor IgG1 with MMAE.
- Payload: MMAE
- Linker: mc-vc-PABC
- Approvals: US 2021: Recurrent/metastatic cervical cancer after chemotherapy (full 2024); EU 2025: Recurrent/metastatic cervical after systemic therapy; 28 Mar 2025
- Dosing: IV infusion over 30 min; 2 mg/kg (max 200 mg) every 3 weeks
- Toxicity (grade 3+): Peripheral neuropathy 6%; Corneal complications 3.2%

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Tisotumab_vedotin
- FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tisotumab%20vedotin

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Recurrent or metastatic cervical cancer](https://onco.cc/cancers/recurrent-metastatic-cervical-cancer/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [Tissue factor](https://onco.cc/targets/tissue-factor/)
- companies: [Genmab](https://onco.cc/companies/genmab/), [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)
- terms: [mc-Val-Cit-PABC](https://onco.cc/terms/mc-vc-pabc/), [MMAE](https://onco.cc/terms/mmae/), [Tubulin inhibitor payloads](https://onco.cc/terms/tubulin-inhibitor-payloads/)
- trials: [A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With](https://onco.cc/trials/nct06459180/), [Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors](https://onco.cc/trials/nct03485209/), [innovaTV 301 / ENGOT-cx12 / GOG-3057](https://onco.cc/trials/innovatv-301/)
- people: [Bradley J. Monk](https://onco.cc/people/bradley-monk/), [Ignace Vergote](https://onco.cc/people/ignace-vergote/)
- key papers: [innovaTV 301: tisotumab vedotin versus chemotherapy as second- or third-line therapy for recurrent cervical cancer](https://onco.cc/key-papers/paper-innovatv-301-tisotumab-nejm-2024/)
- biomarkers: [Tissue factor expression](https://onco.cc/biomarkers/tissue-factor-expression/)

---
JSON: https://onco.cc/api/v1/entities/tisotumab-vedotin.json